Time for more optimism in metastatic breast cancer?
- 1 March 2014
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 40 (2), 220-228
- https://doi.org/10.1016/j.ctrv.2013.09.015
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer, 2012
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabBreast Cancer Research and Treatment, 2012
- Beyond taxanes: the next generation of microtubule-targeting agentsBreast Cancer Research and Treatment, 2011
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJournal of Neuro-Oncology, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002